Cancer treatment with epothilones

Details for Australian Patent Application No. 2004251444 (hide)

Owner Novartis AG

Inventors Sklenar, Ivo; Zaknoen, Sara; Parkinson, David

Agent Davies Collison Cave

Pub. Number AU-B-2004251444

PCT Pub. Number WO2005/000292

Priority 60/483,263 27.06.03 US

Filing date 25 June 2004

Wipo publication date 6 January 2005

Acceptance publication date 22 May 2008

International Classifications

A61K 31/336 (2006.01) - having three-membered rings, e.g. oxirane, fumagillin

A61K 31/365 (2006.01) - Lactones

A61K 31/427 (2006.01) - not condensed and containing further heterocyclic rings

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

12 January 2006 PCT application entered the National Phase

  PCT publication WO2005/000292 Priority application(s): WO2005/000292

22 May 2008 Application Accepted

  Published as AU-B-2004251444

18 September 2008 Standard Patent Sealed

27 January 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004251451-Livestock products with an increased PPAR/RXR heterodimer activator level

2004251439-Tablet comprising fluvastatin and carmellose calcium